REMS Meeting For Opioids Shows Key Role Of Patients
FDA expects to use the two-day open meeting to delve deeper into technical issues of IT and distribution that will inform further risk mitigation programs in other drug classes.
FDA expects to use the two-day open meeting to delve deeper into technical issues of IT and distribution that will inform further risk mitigation programs in other drug classes.